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used to apply hospital- and revenue center-speciﬁc 
cost-to-charge ratios to estimate pharmaceutical costs
from charges at the discharge level. The Diagnosis-
Related Group (DRG) methodology was used to case-mix
adjust the results. Relative value units were derived from
the hospital speciﬁc cost estimates. After trimming at +/-
three standard deviations, cluster analyses methods were
applied to the hospitals to allocate each hospital into one
of four levels of pharmaceutical service intensity.
RESULTS: The data set included 959 acute care hospi-
tals, representing inpatient pharmacy cost information on
more than 6.9 million discharges. The time period was
federal ﬁscal year 2000. DRG 495, lung transplant, was
the most costly group, while the least costly group was
DRG 391, normal newborn. Of the 959 hospitals, 11
(1.15%) were excluded after trimming on intensity score.
The mean relative value score for the remaining 948 
hospitals was 2.77, with a range of 1.17 to 5.02. The
standard deviation was 0.59.
CONCLUSIONS: These results provide empirical 
evidence from a very large sample of hospitals that the
intensity of pharmaceutical interventions in acute care
hospitals in the U.S. exhibits considerable variability. A
four-fold difference was detected in intensity score
between the lowest intensity hospitals and the highest.
This DRG-adjusted difference was not due to differences
in case-mix across hospitals. Further research should 
be done to determine whether patient outcomes are 
associated with low versus high pharmaceutical service
intensity.
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OBJECTIVES: The Pediatric Economic Database 
Evaluation (PEDE) Project features a database of 787
pediatric economic evaluations published between 1980
and 1999. A goal of the PEDE Project is to appraise the
quality of pediatric economic evaluations published over
this period. The objective of this research was to develop
a valid and reliable quality appraisal instrument applica-
ble to economic evaluations in the pediatric population. 
METHODS: A draft instrument was constructed from
published checklists and questionnaires. New questions
pertaining to the pediatric population were incorporated.
An expert panel reviewed the draft instrument and the
proposed scoring scheme for face and content validity. 
A revised version was pilot-tested by three independent
appraisers. After addressing discrepancies in scores, a
ﬁnal version was created and subjected to inter-rater and
test-retest reliability assessment.
RESULTS: The 57 items in the ﬁnal questionnaire were
mapped onto fourteen domains: economic evaluation,
comparators, target population, time horizon, perspec-
tive, costs and resource use, outcomes, quality of life,
analysis, discounting, incremental analysis, sensitivity
analysis, conﬂict of interest, and conclusions. Among the
57 items, 46 have response options that are scored from
0 to 1. Inter-rater reliability was 0.75 (95% CI 0.66–0.81)
and test-retest reliability was 0.92 (95% CI 0.71–0.98).
CONCLUSIONS: The Pediatric Quality Appraisal Ques-
tionnaire is a comprehensive instrument demonstrating
face and content validity and very good reliability for
application in the appraisal of pediatric economic evalu-
ations. The instrument is currently being used in a quality
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OBJECTIVE: To examine the relationship between the
exposure of a patient to direct-to-consumer advertising
(DTCA), and the likelihood of clinician behavioral inten-
tions to provide information and medications. 
METHODS: A randomized mail survey of Arizona
primary care physicians (n = 1080) and physician 
assistants (n = 704) was conducted. Questionnaires 
were created with a hypothetical patient scenario varying
according to the informational exposure of the patient (2
levels: DTCA or drug reference book). All other wording
in the hypothetical scenarios was controlled. Clinicians
were randomly assigned one form of the questionnaire.
Each form solicited responses to questions related to the
likelihood of respondent behavioral intentions (6-point
scale, 6 = very likely to 1 = very unlikely) when faced with
the hypothetical patient scenario.
RESULTS: The response rate for useable questionnaires
was 44% (40.5% physicians and 49.3% physician assis-
tants). No overall statistically signiﬁcant differences were
found between the early responders and late responders.
Also, no statistically signiﬁcant differences were found
between responders and non-responders based on the
metropolitan designations of their practice settings. 
Relative to clinicians who received the “drug reference
book” patient scenario, clinicians who received the
DTCA patient scenario were: more likely to become
annoyed with a patient for asking for more information
about medications (p = 0.003); less likely to answer the
patient’s questions (p = 0.028) or provide additional
written information (p = 0.007); more likely to attempt
to change the subject rather than discuss an advertised
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medication (p = 0.017); more likely to become frustrated
(p = 0.003) and annoyed (p < 0.001) with the patient for
asking to try a medication; and less likely to provide
samples (p = 0.001) or a prescription (p < 0.001) for a
medication. 
CONCLUSION: Clinicians are amenable to patients
asking for drug information and medications, but their
level of receptiveness is associated with the source from
which the patient’s questions originate.
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There exists an ongoing debate regarding the effect of
direct-to-consumer (DTC) advertising spending on drug
prices. The two opposite views are: (a) increase in DTC
advertising spending would be added to drug prices (b)
DTC advertising would increase competition and thus
reduce drug prices.
OBJECTIVE: Explore the relationship of DTC advertis-
ing spending and drug pricing for the top twenty drugs
from 1997 to 2000. 
METHODS: Top twenty drugs were selected on the basis
of their DTC advertising spending (source: Competitive
Media Reporting, NY) for 1997. For analysis, average
wholesale price (AWP) per unit was used from the Blue
Book AWP Unit pricing. For each of the top twenty drugs,
the following trend graphs were plotted for 1997 to 2000:
(a) the total DTC advertising spending and per unit price
of the drug; (b) the percent changes in the DTC advertis-
ing spending and drug price. The percent change in DTC
advertising spending and drug price for a year was 
calculated as percent change from the previous year.
RESULTS: Only sildenaﬁl (Viagra) and sibutramine
(Meridia) showed an increase in the actual drug price
with an increase in the DTC advertising spending.
However, for these two drugs in year 2000, the percent
change in DTC advertising spending decreased and the
percent change in drug price increased. No trend was
evident from the graphs of the other eighteen drugs. On
an average DTC advertising spending for most of the
drugs decreased with time while drug prices continued to
increase. 
CONCLUSION: Results indicate a very weak relation-
ship between DTC advertising spending and drug prices.
The increase in drug price in spite of the decrease in the
DTC advertising spending contradicts both rationale i.e.
DTC advertising spending reduces drug price through
competition or increase in drug price is due to increase in
DTC advertising spending.
HP7
IMPACT OF DIRECT TO CONSUMER
ADVERTISING—THE CONSUMER SEARCH FOR
INFORMATION
Belazi DT1, Crawford A2, Pizzi L2
1Thomas Jefferson University & Abbott Laboratories,
Philadelphia, PA, USA; 2Thomas Jefferson University,
Philadelphia, PA, USA
OBJECTIVE: The purpose of this study is to identify
factors associated with consumers’ seeking various infor-
mation sources about medications sought in response to
direct to consumer advertising. 
METHODS: In the spring and summer of 1999, the FDA,
Division of Drug Marketing, Advertising, and Commu-
nication conducted a national telephone survey of 
adults regarding Direct-to-Consumer (DTC) promotion
of prescription drugs and its effects on visits to the doctor.
In addition to consumer attitudes, opinions and responses
to direct to consumer advertising, the survey also elicited
responses regarding consumer utilization of information
sources such as reference books, 800-telelphone number,
and health care providers. There were 1081 total respon-
dents, of whom 769 completed the required questions
regarding information sources. Chi Square analysis 
was used to assess associations between consumer 
demographic information and the different types of 
informational resources that consumers used after 
exposure of direct to consumer advertising.
RESULTS: The analysis showed signiﬁcant associations
(p £ 0.05) between gender, race, education, health 
status, self-perceived knowledge of health, prescription
medication use, and internet use and many of the 
following information resources: reference books, 
asking friends/neighbors, 800-telephone number, primary
doctor, pharmacist, specialist, and nurse. Across all 
information sources, female gender, decreased health
status, low education, and higher than average medica-
tion use were the variables that had the strongest associ-
ations. A model was developed depicting the associations
between these ﬁndings. Results pertaining to speciﬁc
sources will be presented.
CONCLUSIONS: This study evaluated how different
consumers seek information from different sources as a
result of direct to consumer advertising. This study will
assist those interested in identifying and further educat-
ing consumers about their health and novel treatments or
therapies.
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